Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDMFree Report) by 51.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 125,341 shares of the medical device company’s stock after selling 133,742 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.19% of Tandem Diabetes Care worth $2,603,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. BlackRock Inc. boosted its holdings in Tandem Diabetes Care by 45.1% in the 1st quarter. BlackRock Inc. now owns 9,207,560 shares of the medical device company’s stock worth $373,919,000 after buying an additional 2,861,120 shares during the last quarter. Paradice Investment Management LLC acquired a new position in shares of Tandem Diabetes Care during the 2nd quarter worth approximately $30,106,000. Jennison Associates LLC boosted its holdings in shares of Tandem Diabetes Care by 252.6% during the 3rd quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company’s stock worth $23,323,000 after purchasing an additional 804,488 shares during the last quarter. Chicago Capital LLC boosted its holdings in shares of Tandem Diabetes Care by 699.8% during the 3rd quarter. Chicago Capital LLC now owns 904,410 shares of the medical device company’s stock worth $18,785,000 after purchasing an additional 791,336 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Tandem Diabetes Care during the 2nd quarter valued at approximately $16,127,000.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock opened at $27.34 on Wednesday. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $44.85. The stock’s fifty day simple moving average is $25.80 and its 200-day simple moving average is $23.14. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91.

Analyst Upgrades and Downgrades

TNDM has been the topic of several analyst reports. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Piper Sandler reduced their price target on shares of Tandem Diabetes Care from $40.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. Finally, Stifel Nicolaus lifted their price target on shares of Tandem Diabetes Care from $17.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, February 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $35.33.

Read Our Latest Analysis on TNDM

Tandem Diabetes Care Profile

(Free Report)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Recommended Stories

Institutional Ownership by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.